CD14 overexpression
|
HL
|
CD14 overexpression
|
HL
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
|
CD14 overexpression
|
AML
|
CD14 overexpression
|
AML
|
venetoclax + palbociclib Sensitive: C3 – Early Trials
|
venetoclax + palbociclib Sensitive: C3 – Early Trials
|